Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

The investigational treatment DZD8586 elicited encouraging antitumor activity with manageable toxicity in heavily pretreated ...

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma: Milan Monday, June 16, 2025, 14:00 Hrs [IST] Johnson & Johnson an ...